Medicinal cannabis, CBD and hemp healthcare products company, Bod Australia (ASX: BDA), has announced that prescriptions for its MediCabilis medicinal cannabis product have been received from UK patients participating in Project Twenty21.
The UK-based Project Twenty21 is Europe’s largest medicinal cannabis registry, targeting 20,000 patients.
It is designed to generate a large body of evidence for the efficacy of medicinal cannabis. The registry is targeting patients suffering from conditions including chronic pain, multiple sclerosis, post-traumatic stress disorder, Tourette's syndrome, anxiety disorders and issues arising from substance abuse.
Bod said it expects to supply a minimum of 1,000 patients during the registry with its five per cent MediCabilis CBD product. It said the registry is expected to conclude at the end of 2021 but may continue into 2022.
The company described it as a major milestone because it provides an additional sales channel.
According to CEO Jo Patterson, “The commencement of Project Twenty21 is a major development for Bod and provides the Company with another opportunity to grow in a market estimated to be worth $3Bn by 2024.
“Participation in the registry opens another sales avenue for MediCabilis and will provide the Company with exposure to a large number of physicians, patients and clinics across the country. This is pivotal as Bod continues to build brand awareness across the UK.
“We are confident that the UK will be an important growth market for MediCabilis and these initial patients provide the beginning of what will become a scalable revenue base for the Company."